Blog
RSS FeedPosted by Michael Wonder on 11 Aug 2023
PHARMAC proposes widening access to a brain cancer treatment to help reduce the impact of a discontinuation
11 August 2023 - PHARMAC is proposing to widen access to temozolomide, an oral anti-cancer treatment, for people with a type ...
Posted by Michael Wonder on 10 Aug 2023
PHARMAC’s Rare Disorders Advisory Committee makes new recommendations for funding
10 August 2023 - PHARMAC has published the record of the March Rare Disorders Advisory Committee meeting, sharing details on ...
Posted by Michael Wonder on 03 Aug 2023
PHARMAC secures supply of vaccines for New Zealanders
3 August 2023 - PHARMAC has confirmed supply agreements for a range of funded vaccines including those that protect against ...
Posted by Michael Wonder on 01 Aug 2023
PHARMAC considers access criteria for COVID-19 anti-viral treatments
1 August 2023 - PHARMAC is consulting on changes to the access criteria for all COVID-19 anti-viral treatments to include ...
Posted by Michael Wonder on 31 Jul 2023
New Zealand Pharmaceutical Schedule - 1 August 2023
1 August 2023 - The August 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Jul 2023
PHARMAC’s funding model creating an ‘ethical dilemma’ - specialist
29 July 2023 - The New Zealand Breast Cancer Foundation is renewing calls for PHARMAC to fund Keytruda for the ...
Posted by Michael Wonder on 27 Jul 2023
Molnupiravir will remain available for people who need it
27 July 2023 - PHARMAC has confirmed today that molnupiravir will remain available as a treatment to protect against infection ...
Posted by Michael Wonder on 24 Jul 2023
Shingles can be deadly, so why is the vaccine only free for one year of life?
25 July 2023 - One in three people are at risk of developing shingles in their lifetime and the risk increases ...
Posted by Michael Wonder on 20 Jul 2023
PHARMAC joins international collaboration to advance use of health technology assessments
20 July 2023 - PHARMAC has joined an international collaboration of government health technology assessment agencies. ...
Posted by Michael Wonder on 01 Jul 2023
New Zealand Pharmaceutical Schedule - 1 July 2023
1 July 2023 - The July 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 23 Jun 2023
PHARMAC publishes minutes from February 2023 PTAC meeting
21 June 2023 - The meeting was held on 16-17 February 2023 in person and via Zoom. ...
Posted by Michael Wonder on 22 Jun 2023
PHARMAC considers widening access to treatments for multiple sclerosis and haemophilia A
22 June 2023 - PHARMAC has started a consultation today for widening access for two treatments; ocrelizumab (Ocrevus) as the first ...
Posted by Michael Wonder on 09 Jun 2023
PHARMAC breast cancer cost saving proposal welcome but ignores patients facing “dead-end”
8 June 2023 - Breast Cancer Foundation NZ is urging PHARMAC to widen access to an already funded treatment for ...
Posted by Michael Wonder on 08 Jun 2023
Proposal to widen access to intravenous trastuzumab and change the funded brand
8 June 2023 - The proposal would also give more New Zealanders funded access to intravenous trastuzumab. ...
Posted by Michael Wonder on 07 Jun 2023
PHARMAC confirms funding of rituximab for IgG4 related disease
7 June 2023 - PHARMAC has published a notification for widened access to rituximab (Riximyo) for people with the chronic inflammatory ...